Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. BioMérieux
  6. Summary
    BIM   FR0013280286

BIOMÉRIEUX

(BIM)
  Report
Real-time Euronext Paris  -  11:37:11 2023-05-26 am EDT
95.56 EUR   -0.99%
05/24BioMerieux : A good start to the year
Alphavalue
05/23BIOMÉRIEUX : Share buyback
CO
05/16BioMérieux Triples Footprint in Philadelphia with 32,000 Sq. Ft. Predictive Diagnostics Innovation Center
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
05/22/2023 05/23/2023 05/24/2023 05/25/2023 05/26/2023 Date
100.7(c) 98.86(c) 96.04(c) 96.52(c) 95.56(c) Last
99 769 116 663 87 181 75 349 126 680 Volume
-0.54% -1.83% -2.85% +0.50% -0.99% Change
More quotes
Estimated financial data (e)
Sales 2023 3 713 M 3 974 M 3 974 M
Net income 2023 444 M 475 M 475 M
Net cash position 2023 379 M 405 M 405 M
P/E ratio 2023 26,0x
Yield 2023 0,79%
Sales 2024 3 917 M 4 193 M 4 193 M
Net income 2024 493 M 528 M 528 M
Net cash position 2024 643 M 689 M 689 M
P/E ratio 2024 23,4x
Yield 2024 0,83%
Capitalization 11 269 M 12 061 M 12 061 M
EV / Sales 2023 2,93x
EV / Sales 2024 2,71x
Nbr of Employees 12 846
Free-Float 36,7%
More Financials
Company
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.7%): in industry, microbiological testing of samples from... 
Read more
More about the company
Ratings of bioMérieux
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about BIOMÉRIEUX
05/24BioMerieux : A good start to the year
Alphavalue
05/23BIOMÉRIEUX : Share buyback
CO
05/16BioMérieux Triples Footprint in Philadelphia with 32,000 Sq. Ft. Predictive Diagnostics..
CI
04/28BioMerieux : A good start to the year
Alphavalue
04/27Transcript : BioMérieux S.A., Q1 2023 Sales/ Trading Statement Call, Apr 27, ..
CI
04/27Biomerieux : BioMérieux – First-Quarter 2023 Business Review
PU
04/27BIOMÉRIEUX : 1st quarter turnover
CO
04/17Oxford Nanopore signs partnership agreement with bioMerieux
AN
04/17Oxford Nanopore and Biomerieux to Enter into A Strategic Partnership Agreement to Devel..
CI
04/13Biomerieux : BioMérieux receives US FDA 510(k) clearance for the BIOFIRE® SPOTFIRE® Respir..
PU
04/07Biomerieux : Mars 2023 - Déclaration sur le nombre d'actions composant le capital social e..
PU
04/07Biomerieux : SPECIFIC REVEAL™ Rapid AST System, newly renamed VITEK® REVEAL™, ..
PU
04/05Biomerieux : BioMérieux launches BIOFIRE® FIREWORKS™, a cutting-edge, data-driven so..
PU
03/22BIOMÉRIEUX : Universal registration document
CO
03/21Proxim Diagnostics Corp. announced that it has received funding from bioMérieux S.A.
CI
More news
News in other languages on BIOMÉRIEUX
05/25Opiniones de los analistas del día: CaixaBank, Aixtro..
05/25Nvidia fait sauter la banque
05/25Avis d'analystes du jour : Sartorius Stedim Biotech, Soitec, bi..
05/24BioMerieux : Un bon début d'année
05/23Biomerieux : AG 2023 - Descriptif programme rachat d'actions
More news
Analyst Recommendations on BIOMÉRIEUX
More recommendations
Stock Trading Strategies
BIOMÉRIEUX - 03/09
Good timing to go long again
BUY
More Stock Trading Analysis
ETFs positioned on BIOMÉRIEUXETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
HAN-GINS Indxx Healthcare Megatrend Equal W...0.92%-1.72%-NC
Mackenzie Maximum Diversification Developed...0.8%-1.98%Europe
BNP PARIBAS EASY MSCI EMU SRI S-Series PAB ...0.62%-2.00%-Europe
Wealthsimple Developed Markets ex North Ame...0.51%-2.35%-NC
IShares MSCI EMU Mid Cap - EUR0.47%-2.41%Europe
More ETFs positioned on BIOMÉRIEUX
Chart BIOMÉRIEUX
Duration : Period :
bioMérieux Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMÉRIEUX
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 95,56 €
Average target price 105,75 €
Spread / Average Target 10,7%
EPS Revisions
Managers and Directors
Alexandre Mérieux Chairman & Chief Executive Officer
Guillaume Bouhours EVP-Finance, Purchasing & Information Systems
Alain Mérieux Chairman
François Lacoste Executive Vice President-Research & Development
Mark Miller Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BIOMÉRIEUX-2.41%12 061
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.21.66%6 787
LANTHEUS HOLDINGS, INC.78.67%6 222
10X GENOMICS, INC.45.12%6 144
DIASORIN S.P.A.0.00%5 683
AUTOBIO DIAGNOSTICS CO., LTD.-5.53%4 805
-40% off: Our subscriptions help you unlock hidden opportunities!
Subscribe
fermer